Castle Biosciences, Inc. products

Uveal melanoma, commonly known as ocular or choroidal melanoma, is a rare cancer of the eye with approximately 2,000 patients diagnosed annually in the U.S. At the time of initial diagnosis, approximately 97% of patients are free of metastasis.  However, within five years, approximately 30% of patients will develop metastasis – rising to nearly 50% in the following years.

Castle Biosciences offers DecisionDx-PRAME gene expression profile testing to assess expression of the PRAME (preferentially expressed antigen in melanoma) gene. DecisionDx-PRAME is an optional, additional test that can be run on the same sample as your DecisionDx^®-UM GEP (gene expression profile) test.

Our DecisionDx-UMSeq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma.  Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as possible about a uveal melanoma tumor from a single biopsy. To provide additional genetic information from your biopsy, Castle Biosciences offers an optional gene sequencing panel that can find mutations in seven important genes in your uveal melanoma tumor.